Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 1/20 | 0.37 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | GSK3A | P49840 | 3/20 | 0.33 |
| ▸ | GSK3B | P49841 | 2/20 | 0.33 |
| ▸ | PDE3B | Q13370 | 2/20 | 0.33 |
| ▸ | PDE3A | Q14432 | 2/20 | 0.33 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.31 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31226285 | 0.82 | TDP1 (0.36) | TDP1 | |
| SCHEMBL30893809 | 0.78 | CYP1A2 (0.48) | TDP1 | |
| SCHEMBL2647859 | 0.75 | MAPT (0.46) | CNR2TDP1 | |
| SCHEMBL30378500 | 0.75 | MAPT (0.46) | CNR2TDP1 | |
| SCHEMBL30282824 | 0.75 | BPTF (0.51) | ADRB2 | |
| SCHEMBL23879247 | 0.75 | ALDH1A1 (0.38) | TDP1HRH3 | |
| SCHEMBL30453647 | 0.75 | ALDH1A1 (0.38) | TDP1HRH3 | |
| SCHEMBL24961672 | 0.74 | MAP3K12 (0.36) | CNR2 | |
| SCHEMBL24962239 | 0.74 | SCN10A (0.30) | — | |
| SCHEMBL30893815 | 0.73 | CNR2 (0.34) | CNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115677730-B | 8-Oxo-3-azabicyclo [3.2.1] octane compound or salt thereof, and preparation method and application thereof | 励缔(杭州)医药科技有限公司 | 2024-11-12 | — | — | CN | disclosed |
| US-20240294550-A1 | 8-OXA-3-AZABICYCLO[3.2.1]OCTANE COMPOUNDS OR SALT THEREOF, AND PREPARATION METHOD AND USE THEREOF | LITTDD MEDICINES LTD (CN) | 2024-09-05 | — | — | US | disclosed |
| EP-4378943-A1 | 8-OXO-3-AZABICYCLO[3.2.1]OCTANE COMPOUND OR SALT THEREOF, AND PREPARATION METHOD THEREFOR AND USE THEREOF | Littdd Medicines Ltd (CN) | 2024-06-05 | — | — | EP | disclosed |
| CN-118043325-A | 8-Oxo-3-azabicyclo [3.2.1] octane compound or salt thereof, and preparation method and application thereof | 励缔(杭州)医药科技有限公司 | 2024-05-14 | — | — | CN | disclosed |
| CN-115677730-A | 8-oxygen-3-azabicyclo [3.2.1] octane compound or salt thereof, and preparation method and application thereof | 上海辉启生物医药科技有限公司 | 2023-02-03 | — | — | CN | disclosed |
| WO-2023005928-A1 | 8-OXO-3-AZABICYCLO[3.2.1]OCTANE COMPOUND OR SALT THEREOF, AND PREPARATION METHOD THEREFOR AND USE THEREOF | 上海辉启生物医药科技有限公司 | 2023-02-02 | — | — | WO | disclosed |
| WO-2023005928-A1 | 8-OXO-3-AZABICYCLO[3.2.1]OCTANE COMPOUND OR SALT THEREOF, AND PREPARATION METHOD THEREFOR AND USE THEREOF | 上海辉启生物医药科技有限公司 | 2023-02-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240294550-A1 | 8-OXA-3-AZABICYCLO[3.2.1]OCTANE COMPOUNDS OR SALT THEREOF, AND PREPARATION METHOD AND USE THEREOF | ATR, OGG1, ATRIP | CNR2 4538/4885ADRB2 1036/4885TDP1 23/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.